| scholarly article | Q13442814 |
| P2093 | author name string | Alice L Rodriguez | |
| Carrie K Jones | |||
| Colleen M Niswender | |||
| Corey R Hopkins | |||
| Craig W Lindsley | |||
| P Jeffrey Conn | |||
| Andrew S Felts | |||
| Julie L Engers | |||
| Kyle A Emmitte | |||
| John E Macor | |||
| Joseph D Panarese | |||
| Joanne J Bronson | |||
| Michael A Nader | |||
| Anna L Blobaum | |||
| Darren W Engers | |||
| Matthew T Loch | |||
| Yong-Jin Wu | |||
| Arlindo L Castelhano | |||
| Aspen Chun | |||
| Michael J Kates | |||
| P2860 | cites work | Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease | Q22252880 |
| Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs) | Q24650602 | ||
| Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system | Q28564596 | ||
| Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS | Q28569174 | ||
| Pharmacology and functions of metabotropic glutamate receptors | Q29619150 | ||
| Epidemiology of Parkinson's disease. | Q30238651 | ||
| The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. | Q30458705 | ||
| Pathophysiology of L-dopa-induced dyskinesias. | Q33736384 | ||
| Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders | Q34125116 | ||
| Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems | Q34131401 | ||
| Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs | Q34347785 | ||
| Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4). | Q34522043 | ||
| Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers | Q34534818 | ||
| Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors | Q37183072 | ||
| Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities | Q37264464 | ||
| Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. | Q37597284 | ||
| mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. | Q37693720 | ||
| Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics | Q38031832 | ||
| Direct and indirect pathways of basal ganglia: a critical reappraisal | Q38234309 | ||
| A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists | Q39729700 | ||
| Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia | Q42719140 | ||
| Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. | Q47808755 | ||
| Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. | Q48478225 | ||
| Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. | Q49348243 | ||
| Deep brain stimulation in early stage Parkinson's disease may reduce the relative risk of symptom worsening. | Q52145441 | ||
| Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease | Q57174015 | ||
| 2-Position-Selective C-H Perfluoroalkylation of Quinoline Derivatives | Q88000661 | ||
| Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability | Q89352662 | ||
| Recruitment and Retention in Clinical Trials of Deep Brain Stimulation in Early-Stage Parkinson's Disease: Past Experiences and Future Considerations | Q90231745 | ||
| Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor | Q91685052 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 255-260 | |
| P577 | publication date | 2018-10-16 | |
| P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
| P1476 | title | Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease | |
| P478 | volume | 10 |
| Q89993515 | Roles of Glutamate Receptors in Parkinson's Disease | cites work | P2860 |
Search more.